MX371277B - Fármaco a base de maghemita para la reducción simultánea de la resorción de sodio y la resorción de fosfato gastrointestinales. - Google Patents

Fármaco a base de maghemita para la reducción simultánea de la resorción de sodio y la resorción de fosfato gastrointestinales.

Info

Publication number
MX371277B
MX371277B MX2017008775A MX2017008775A MX371277B MX 371277 B MX371277 B MX 371277B MX 2017008775 A MX2017008775 A MX 2017008775A MX 2017008775 A MX2017008775 A MX 2017008775A MX 371277 B MX371277 B MX 371277B
Authority
MX
Mexico
Prior art keywords
resorption
maghemite
phosphate
drug based
simultaneous reduction
Prior art date
Application number
MX2017008775A
Other languages
English (en)
Other versions
MX2017008775A (es
Inventor
Wagner Susanne
Taupitz Matthias
Schnorr Jörg
Kratz Harald
EBER Monika
Stolzenburg Nicola
Gläser Janna
Hauptmann Ralf
BREINL Janni
Ariza DE SCHELLENBERGER Angela
GEMEINHARDT Ines
Original Assignee
Univ Berlin Charite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Berlin Charite filed Critical Univ Berlin Charite
Publication of MX2017008775A publication Critical patent/MX2017008775A/es
Publication of MX371277B publication Critical patent/MX371277B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Abstract

La invención comprende una sustancia basada en maghemita nanocristalina con un tamaño de cristal de entre 0,5 y 4 ran, que define un porcentaje de magnetita por el porcentaje de iones de hierro bivalentes menor de cinco de cien porcentajes en peso del hierro total y reduce el transporte de sodio y al mismo tiempo de fosfato en la pared estomacal e intestinal del contenido gastrointestinal en la circulación sanguínea y con ello puede mejorar el desequilibrio del balance de electrolitos, agua y minerales en el caso de una aplicación oral junto con coadyuvantes farmacéuticos adecuados.
MX2017008775A 2014-12-29 2015-12-28 Fármaco a base de maghemita para la reducción simultánea de la resorción de sodio y la resorción de fosfato gastrointestinales. MX371277B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102014019388.8A DE102014019388A1 (de) 2014-12-29 2014-12-29 Arzneimittel auf der Basis von Maghämit zur gleichzeitigen Reduzierung der gastrointestinalen Natriumresorption und Phosphatresorption
PCT/DE2015/000608 WO2016107619A1 (de) 2014-12-29 2015-12-28 Arzneimittel auf der basis von maghämit zur gleichzeitigen reduzierung der gastrointestinalen natriumresorption und phosphatresorption

Publications (2)

Publication Number Publication Date
MX2017008775A MX2017008775A (es) 2018-03-23
MX371277B true MX371277B (es) 2020-01-24

Family

ID=55411127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008775A MX371277B (es) 2014-12-29 2015-12-28 Fármaco a base de maghemita para la reducción simultánea de la resorción de sodio y la resorción de fosfato gastrointestinales.

Country Status (11)

Country Link
US (1) US10632149B2 (es)
EP (1) EP3240531B1 (es)
JP (1) JP6676056B2 (es)
KR (1) KR102114827B1 (es)
CN (1) CN107257682B (es)
AU (1) AU2015373628B2 (es)
CA (1) CA2970754C (es)
DE (1) DE102014019388A1 (es)
MX (1) MX371277B (es)
WO (1) WO2016107619A1 (es)
ZA (1) ZA201704222B (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
DE19547356A1 (de) 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
EP1216060A2 (de) * 1999-09-14 2002-06-26 Biomedical Apherese Systeme GmbH Magnetische nanoteilchen mit biochemischer wirksamkeit und verfahren zu ihrer herstellung sowie ihre verwendung
MXPA03003584A (es) * 2000-11-14 2003-07-14 Vital Health Sciences Pty Ltd Formulacion que contiene derivados de fosfato de agentes de transferencia de electrones.
KR100487905B1 (ko) * 2002-10-02 2005-05-06 한국과학기술연구원 형상이방성 산화철 나노분말 및 그 제조방법
JP2007516216A (ja) * 2003-09-12 2007-06-21 バンクラプシー エステート オブ ファークス， インコーポレイテッド 生物学的に活性な因子の部位特異的送達のための、磁気成分および生体適合性ポリマーを含む磁気標的化可能な粒子
EP1738774A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzungen und deren Verwendung in bildgebenden Verfahren
EP2591804A3 (en) * 2007-09-24 2014-04-16 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
MX345283B (es) 2008-12-31 2017-01-24 Ardelyx Inc Compuestos y metodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrogeno (nhe) en el tratamiento de trastornos asociados con retencion de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
JP5734285B2 (ja) * 2009-06-26 2015-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 薄片状基材およびマグヘマイトの層を含む磁性顔料
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006473A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CN101985003A (zh) * 2010-11-18 2011-03-16 苏州市天灵中药饮片有限公司 一种具有补肾纳气功效的药酒
DE102011112898A1 (de) 2011-09-08 2013-03-14 Charité - Universitätsmedizin Berlin Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen
CN104225088A (zh) * 2014-10-06 2014-12-24 李先强 治疗慢性肺心病的混合中药

Also Published As

Publication number Publication date
MX2017008775A (es) 2018-03-23
EP3240531B1 (de) 2020-02-12
DE102014019388A1 (de) 2016-06-30
US10632149B2 (en) 2020-04-28
JP6676056B2 (ja) 2020-04-08
WO2016107619A1 (de) 2016-07-07
CA2970754A1 (en) 2016-07-07
KR102114827B1 (ko) 2020-05-25
CN107257682B (zh) 2021-03-02
EP3240531A1 (de) 2017-11-08
KR20170102901A (ko) 2017-09-12
AU2015373628B2 (en) 2019-01-03
CA2970754C (en) 2021-09-21
ZA201704222B (en) 2021-01-27
CN107257682A (zh) 2017-10-17
US20170348351A1 (en) 2017-12-07
JP2018506516A (ja) 2018-03-08
AU2015373628A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
MX2019014045A (es) Composiciones y metodos.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
PL2753343T3 (pl) Kompozycja zawierająca n-acetylocysteinę oraz bakterie probiotyczne zdolne do przywrócenia własnego działania barierowego żołądka, które zostaje zniszczone podczas leczenia nadkwaśności soku żołądkowego inhibitorami pompy protonowej
IN2015DN01104A (es)
NZ717739A (en) Compounds and methods for inhibiting phosphate transport
IN2014DN06737A (es)
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2019005435A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
RU2015145997A (ru) Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат
MX2023007706A (es) Nanoparticulas para su uso como vacuna terapeutica.
SMT201600460B (it) Composizione farmaceutica per uso nel trattamento o prevenzione delle carenze di vitamine e minerali in pazienti che sono stati sottoposti a chirurgia di bypass gastrico
MX371277B (es) Fármaco a base de maghemita para la reducción simultánea de la resorción de sodio y la resorción de fosfato gastrointestinales.
GB201208080D0 (en) Tobramycin formulation
NZ707033A (en) Dispersible nimorazole tablet
CL2020001926A1 (es) Uso de carbonato de calcio funcionalizado como ingrediente activo.
RU2014106575A (ru) Способ профилактики кровотечения при миомэктомии
Caocci Diarrhoea: case report
Qu Diarrhoea: case report
Cante Docetaxel/gemcitabine
Robinson Editorial Comment to Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study
MY194945A (en) Oral administration of unstable or poorly-absorbed drugs
Bossi Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol 2011; 59: 1009-18
Lesiak Adalimumab/infliximab/ustekinumab
UA83680U (ru) Способ комплексной реабилитации больных нейродермитом
Inrhaoun Facial ichthyosis and diarrhoea in an elderly patient: case report

Legal Events

Date Code Title Description
FG Grant or registration